S103: EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Lignende værker

• S103: EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
  af: C. Fernandez De Larrea, et al.
  Udgivet: (2022-06-01)
• Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h
  af: Daniel Munárriz, et al.
  Udgivet: (2025-10-01)
• Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT
  af: Víctor Torrecillas-Mayayo, et al.
  Udgivet: (2026-05-01)
• Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
  af: Inés Zugasti, et al.
  Udgivet: (2025-02-01)
• The Timing and Polarization of PSR J0002+6216
  af: Y. Wei, et al.
  Udgivet: (2025-01-01)